Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI

In the clinical trial, OTX-CSI was administered by a physician as a bioresorbable intracanalicular insert to both eyes in five subjects with DED. (Credit: Free-Photos from Pixabay)